secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001437749-24-026908
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma narrows Q2 net loss to $7.9M; secures $10.8–16.3M convertible debt for NDAs
--------------------------------------------------------------------------------

- Q2 net loss $7.9M vs $8.7M YoY; six-month net loss $14.4M vs $19.8M.
- Secured $10.8–16.3M convertible debt from Anson Funds; retired Streeterville debt at litigation discount.
- Plans to file NDAs for NRX-100 (IV ketamine) and NRX-101 for bipolar depression in Q4 2024.
- HOPE Therapeutics audit complete; spinout SEC filing planned this quarter.
- Cash $1.9M at June 30; new funding expected to support filings and operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924026908/0001437749-24-026908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924026908/nrxp20240814d_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer